Defence Therapeutics (DTCFF) Stock Statistics & Valuation Metrics
Total Valuation
Defence Therapeutics has a market cap or net worth of $18.98M. The enterprise value is $31.08M.
- Market Cap
- $18.98M
- Enterprise Value
- $31.08M
Share Statistics
Defence Therapeutics has 75,788,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 75,788,155
- Owned by Insiders
- 9.98%
- Owned by Institutions
- ―
Financial Efficiency
Defence Therapeutics’s return on equity (ROE) is -1.91 and return on invested capital (ROIC) is -94.25%.
- Return on Equity (ROE)
- -1.91
- Return on Assets (ROA)
- -1.03
- Return on Invested Capital (ROIC)
- -94.25%
- Return on Capital Employed (ROCE)
- -0.95
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.34M
- Employee Count
- 5
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Defence Therapeutics is -3.17. Defence Therapeutics’s PEG ratio is 0.07.
- PE Ratio
- -3.17
- PS Ratio
- 0.00
- PB Ratio
- 7.56
- Price to FCF
- -5.57
- Price to Operating Cash Flow
- -6.11
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Defence Therapeutics had revenue of 0 and earned -6.70M in profits. Earnings per share was -0.11.
- Revenue
- 0
- Gross Profit
- -72.11K
- Operating Income
- -4.99M
- Pretax Income
- -6.78M
- Net Income
- -6.70M
- EBITDA
- -4.92M
- Earnings Per Share (EPS)
- -0.11
Cash Flow
In the last 12 months, operating cash flow was -4.34M and capital expenditures -419,627, giving a free cash flow of -4.76M billion.
- Operating Cash Flow
- -4.34M
- Free Cash Flow
- -4.76M
- Free Cash Flow per Share
- -0.06
Dividends & Yields
Defence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -17.95%
- Earnings Yield
- -25.20%
Stock Price Statistics
- Beta
- -0.37
- 52-Week Price Change
- -54.62%
- 50-Day Moving Average
- 0.32
- 200-Day Moving Average
- 0.36
- Relative Strength Index (RSI)
- 43.46
- Average Volume (3m)
- 12.50K
Important Dates
Defence Therapeutics upcoming earnings date is Nov 20, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Nov 20, 2026
- Ex-Dividend Date
- ―
Financial Position
Defence Therapeutics as a current ratio of 3.42, with Debt / Equity ratio of 48.91%
- Current Ratio
- 3.42
- Quick Ratio
- 3.42
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.03
- Interest Coverage Ratio
- -12.15
Taxes
In the past 12 months, Defence Therapeutics has paid -86.88K in taxes.
- Income Tax
- -86.88K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Defence Therapeutics EV to EBITDA ratio is -4.12, with an EV/FCF ratio of -5.54.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.12
- EV to Free Cash Flow
- -5.54
- EV to Operating Cash Flow
- -6.07
Balance Sheet
Defence Therapeutics has $1.88M in cash and marketable securities with $1.72M in debt, giving a net cash position of $161.32K billion.
- Cash & Marketable Securities
- $1.88M
- Total Debt
- $1.72M
- Net Cash
- $161.32K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Defence Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -56.67%
